AstraZeneca

News

Trump's pharma tariffs haven't appeared yet, but AstraZeneca has joined several of its peers with big investments in US manufacturing and R&D.

News

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

News

The UK has unveiled its plan to revitalise the life sciences sector and become a global leader by 2030, but a pharma trade group says it falls short.

News

AstraZeneca's light chain (AL) amyloidosis candidate anselamimab has failed a phase 3 readout, but showed efficacy in a patient subgroup.

News

LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.

News

Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.